PUBLIC COMPANY
saveTranscend Therapeutics Inc
updated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
- phase3An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSD
- phase2A Study to Assess the Use of Methylone in the Treatment of PTSD
- phase2An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD
- phase2An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD
- phase1A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy Subjects
🐶 Hiring Signal
News
- As ‘cultural weight’ of a psychedelic approval looms, FDA hearing focuses on access and safetyAs the FDA marches toward the likely first approval of a psychedelic medicine, the agency today convened a hearing seeking public input on how these drugs should be used, monitored and continuously…fiercebiotech · 19d ago
- Psychedelic therapies ride wave of public favor into FDA hearingHeading into an FDA hearing on Monday regarding the future of psychedelic treatments, public comments show wide support for further exploring the therapeutic potential of these compounds—to match r…biospace · 19d ago
- Psilocybin proves promising in neuropathic pain mouse studyAmid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.fiercebiotech · 1mo ago
- Psychedelics on the cusp of market breakthrough as clinical, policy support growWhile there are several FDA-approved psychiatric medicines on the market, many patients still struggle to achieve lasting symptom relief. Psychedelics could help fill this gap.biospace · 1mo ago
- Lilly’s $3.8B psychedelics bet won’t open the M&A floodgatesEli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unl…biospace · 2mo ago
- Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelicsEli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…biospace · 2mo ago
- ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicsAfter Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.fiercebiotech · 2mo ago
- Lilly to buy AtaiBeckley for $2.8B, further validating psychedelicsThe latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.biopharma_dive · 2mo ago
- STAT+: FDA to speed up review of three psychedelics as mental health treatmentsTrump's embrace of psychedelics and cannabis is shaking up the GOP’s relationship with mind-altering substances.stat · 5mo ago
comments(0)
5-min edit window · permanent after that